Skip to main content

Table 3 Comparison between the two studied groups according to aspirin use

From: Role of aspirin discontinuation in recurrence of ischemic cerebrovascular stroke

 

Cases (n = 104)

Control (n = 104)

Test of sig.

p

Aspirin Discontinuation

53 (51.0%)

30 (28.8%)

χ2 = 9.100*

0.003*

Cause of discontinuation

 Switch to other antiplatelet

9 (8.7%)

5 (4.8%)

χ2 = 0.006

0.997

 Non compliance

32 (30.8%)

18 (17.3%)

 Side effects

12 (11.5%)

7 (6.7%)

 Over the counter use

0 (0%)

0 (0%)

Time of discontinuation (days)

 0–7

0 (0%)

6 (5.8%)

χ2 = 16.249*

< 0.001*

 8–30

25 (24%)

18 (17.3%)

 31–180

13 (12.5%)

4 (3.8%)

  > 181

15 (14.4%)

2 (1.9%)

Other drug discontinuation

 No

77 (74%)

66 (63.5%)

χ2 = 3.156

0.237

 Statins

25 (24%)

33 (31.7%)

 Antihypertensives

2 (1.9%)

5 (4.8%)

 History of NSAID use

2 (1.9%)

13 (12.5%)

χ2 = 8.694*

0.003*

  1. Data were described using number and percent, in mean ± SD or in median (Min.–Max.)
  2. *Statistically significant at p ≤ 0.05